Skip to Content

Gauri R. Varadhachary, MBBS, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1991 L.T.M. Medical College, University of Mumbai, Mumbai, Maharashtra, India, MBBS, Bachelor of Medicine and Bachelor of Surgery

Postgraduate Training

7/1996-6/1997 Clinical Rotations, Melanoma, Sarcoma, Lymphoma, Leukemia, M. D. Anderson Cancer Center, Houston, TX
7/1994-6/1997 Clinical Fellowship, Hematology and Oncology, Baylor College of Medicine, Houston, TX
7/1991-6/1994 Clinical Residency, Internal Medicine, Greater Baltimore Medical Center (GBMC), Baltimore, MD

Board Certifications

1/1998 American Board of Internal Medicine (Medical Oncology)
1/1998 American Board of Internal Medicine (Hematology)
1/1994 American Board of Internal Medicine (Internal Medicine)
1/1991 ECFMG

Selected Publications

Peer-Reviewed Original Research Articles
1. Varadhachary GR, Raber MN. Gene Expression Profiling in Cancers of Unknown Primary. Journal of Clinical Oncology 27(4):651, 7/2009.
2. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. Ann Surg Oncol, 2009 Feb 5, 2/2009. PMID: 19194760.
3. Varadhachary GR, Greco FA. Overview of patient management and future directions in unknown primary carcinoma. Semin Oncol 36(1):75-80, 2/2009.
4. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol, 1/2009.
5. Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA. The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiother, 1/2009.
6. Varadhachary GR, Abbruzzese JL. Novel approaches to 'borderline resectable' pancreatic tumors. Oncology 22(13):1529-30, 2008 Nov 30, 11/2008. PMID: 19227575.
7. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113(8):2046-52, 10/2008.
8. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26(27):4442-8, 9/2008.
9. Wolff RA, Varadhachary GR, Evans DB. Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress. Annals of Surgical Oncology, 7/2008. PMID: 18640929.
10. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PWT, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative Gemcitabine-based Chemoradiation for Patients with Resectable Adenocarcinoma of the Pancreatic Head. J Clin Oncol 26(21):3496-502, 7/2008. PMID: 18640930.
11. Varadhachary GR, Wolff Ra, Crane CH, Sun CC, Lee JE, Pister PWT, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative Gemcitbine and Cisplatin followed by Gemcitabine-based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. J Clin Oncol 26(21):3487-95, 7/2008. PMID: 18640929.
12. Varadhachary GR, Raber MN, Abbruzzese JL. Colon Cancer Profile, Carcinoma of Unknown Primary. Changing paradigm and emerging definitions. Lancet Oncol 9(6):596-9, 6/2008.
13. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445-454, 6/2008.
14. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833-46, 3/2008.
15. Falchook GS, Wolff RA, Varadhachary GR. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol 108(3):515-9, 3/2008. PMID: 18164378.
16. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys 70(3):735-43, 3/2008. PMID: 17980502.

Invited Articles
1. Varadhachary GR, Crane CH, Evans DB. Preoperative therapy for patients with resectable adenocarcinoma of the pancreatic head. Am Journal Hematology and Oncology. In Press.
2. Varadhachary GR, and Abbruzzese JL. Commentary - Borderline Resectable Pancreatic Cancer. Oncology, 12/2008.
3. Varadhachary, GR. Carcinoma of Unknown Primary. Am Journal of Hematology and Oncology. Submitted.

Abstracts
1. Javle M, Varadhachary G, Bhosale P, Schroff R, Ukegbu L, Overman M, Wolff R, Abbruzzese J. Phase I Study of MK-0646, The Humanized Monoclonal Antibody Against IGF-1R in Combination with Gemcitabine or Gemcitabine + Erlotinib (E) for Advanced Previously Untreated Pancreatic Cancer, 9/2009.
2. Varadhachary GR, McConkey D, Woonyoung C, Marquis L, Carlson H, Bullock S, Abbruzzese JL. A Phase II Study of Bortezomib in Combination with Carboplatin in Patients with Metastatic Pancreatic Cancer. 11th World Congress on Gastrointestinal Cancer, 6/2009.
3. Parker PA, Baile W, Cohen I, Abbruzzese J, Varadhachary G, Ho L, LaPushin T, Dayao P, Lenzi R. Illness uncertainty, sense of coherence, and psychosocial adjustment in patients with pancreatic cancer. Annals of Behavioral Medicine 37(51), 4/2009.
4. D.R. Fogelman, G. Varadhachary, H.Q. Xiong, D.Z. Chang, S.A. Bullock, H. Ozer, R.A. Wolff, J.L. Abbruzzese. Final results of a bi-institution phase II study of gemcitabine, oxaliplatin, and bevacizumab for advanced pancreatic cancer. Proc Am Soc Clin Onc 2009 GI ASCO Symposium (#182), January 2009, 1/2009.
5. R.T. Shroff, S. Krishnan, M. Javle, G.R. Varadhachary, C.H. Crane, S. Wen, J.L. Abbruzzese, R.A. Wolff, M.J. Overman. Improved relapse-free survival with the addition of systemic chemotherapy to adjuvant chemoradiationt for high-risk ampullary adenocarcinoma. Proc Am Soc Clin Oncol 2009 GI ASCO Symposium (#250), 1/2009.
6. R.T. Shroff, H.Q. Xiong, G.R. Varadhachary, A. Kaseb, D.R. Fogelman, L.T. Ukegbu, J.C. Blais, R.A. Wolff, J.L. Abbruzzese, M. Javle. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. Proc Am Soc Clin Oncol 2009 GI ASCO Symposium (#246), January 2009, 1/2009.
7. N. Hammad, P.A. Phillip, A.F. Shields, F.H. Sarkar, J.L. Abbruzzese, A.O. Kaseb, M.M. Javle, G.R. Varadhachary, R.A.Wolff, B.F. El-Rayes. A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer. Proc Am Soc Clin Oncol (#15540), May 20, 5/2008.
8. M.J. Overman, G.R. Varadhachary, E. Lin, J. Morris, R. Adinin, J.L. Abbruzzese, R.A. Wolff. Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater. Proc Am Soc Clin Oncol 2008 Annual Meeting (#4538), May 20, 5/2008.
9. MH Katz, JB Fleming, CC Sun, RA Wolff, CH Crane, DB Evans, GR Varadhachary. Preoperative CA 19-9 in the Neoadjuvant Treatment of Resectable Pancreatic Cancer. Pancreas Club, 5/2008.
10. G.R. Varadhachary, R.A. Wolff, C.H. Crane, J.E. Lee, E.K. Abdalla, J.H. Lee, P.W. Pisters, L. Ho, J.L. Abbruzzese, D.B. Evans. Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2008 Annual Meeting (#4630), May 20, 5/2008.
11. N. Hammad, P.A. Philip, A.F. Shields, J.L. Abbruzzese, A.O. Kaseb, M.M. Javle, G.R. Varadhachary, R.A. Wolff, F. H. Sarkar, B.F. El-Rayes. A phase II study of isoflavone (Novasoy), gemcitabine, and erlotinib in locally advanced or metastatic pancreatic cancer. Gastrointestinal Cancers Symposium, 1/2008.
12. M.M. Javle, T. Okazaki, R.A. Wolff, G. Varadhachary, L. Ho, C.H. Crane, A. San Miguel, D.B. Evans, J.L. Abbruzzese, D. Li. Combined effect of single nucleotide polymorphisms of gemcitabine metabolic genes on pancreatic cancer survival and drug toxicity. ASCO Gastrointestinal Cancers Symposium, 1/2008.
13. S.H. Settle, C.H. Crane, P. Das, G. Varadhachary, E.P. Tamm, M. Javle, J.C. Hodges, S. Krishnan, D.B. Evans, R.A. Wolff. Novel use of focal high-dose IMRT for borderline resectaable pancreatic cancer. ASCO Gastrointestinal Cancers Symposium, 1/2008.
14. G.R. Varadhachary, R.A. Wolff, C.H. Crane, J.E. Lee, E.K. Abdalla, J.H. Lee, P.W. Pisters, L. Ho, J.L. Abbruzzese, D.B. Evans. Preoperative gemcitabine plus bevacizumab-based chemoradiation for resectable pancreatic adenocarcinoma. ASCO Gastrointestinal Cancers Symposium, 1/2008.
15. Javle M, Shroff R, Fleming JB, Lee J, Varadhachary GR, Abbruzzese JL, Wolff RA, Cantor SB, Krishnan S. Cost-effectiveness of neoadjuvant (NeoAdj) vs. adjuvant (Adj) therapies for resectable pancreatic cancer (PC). Submitted.

Book Chapters
1. Katrina Y. Glover, Gauri R. Varadhachary, Renato Lenzi, Martin N. Raber, James L. Abbruzzese. Carcinoma of Unknown Primary. In: Clinical Oncology, Fourth Edition. Churchill Livingstone, 2057-2074, 2008. PMID: 978--0-443-06694-8.
2. Gauri R. Varadhachary, James Abbruzzese. Carcinoma of Unknown Primary. In: Harrison's Principles of Internal Medicine, 2008.
3. C.P. Raut, G. Varadhachary, H. Wang, E. Tamm, J.B. Fleming, D.B. Evans. Margin Status following Pancreaticoduodenectomy for Pancreatic Cancer. In: Diseases of the Pancreas-Current Surgical Therapy. Chapter 54, Beger Matsuno and Cameron. Springer, 611-623, 2008.
4. Gauri R. Varadhachary, James Abbruzzese. Resected Pancreatic Cancer. In: Diseases of the Pancreas-Current Surgical Therapy. Chapter 59, Beger Matsuno and Cameron. Springer, 675-687, 2008.

Letters to the Editor
1. Hainsworth JD, Greco AF, Talantov D, Varadhachary, GR. Reply to “Morphologic and More Specific Immunohistochemical Stains are Fundamental Prerequisites in Detection of Unknown Primary Cancer” by Giulio Rossi et al. Journal of Clinical Oncology:651-652, 2/2009.

Manuals, Teaching Aids, Other Teaching Publications
1. Varadhachary GR. When the Diagnosis is Cancer of Unknown Primary: Guidelines for Care. CancerCare Telephone Workshop: New York, 6/2009.
2. Varadhachary GR, Crane CH, Evans DB, Tamm E. Virtual Pancreatic Tumor Board. Interactive Web based education. Postgraduate Institute for Medicine and IMPACt, Inc. Houston, Texas, 9/2008.
3. OncoLog. 53, 3. Scientific Publications: Houston, Texas, 1-5, 3/2008.

Last updated: 10/22/2009